🇺🇸 FDA
Patent

US 10562975

CD6 antibody for treatment of T-cell mediated diseases or disorders

granted A61KA61K2039/505A61P

Quick answer

US patent 10562975 (CD6 antibody for treatment of T-cell mediated diseases or disorders) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61P, A61P37/06